Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calistoga Pharmaceuticals Inc.

Division of Gilead Sciences Inc.
www.calistogapharma.com

Latest From Calistoga Pharmaceuticals Inc.

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma

Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.

Financing Business Strategies

TG Therapeutics Builds A Business Model For Today

The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.

BioPharmaceutical Strategy

Frazier capitalizes on Calistoga, recruits former CEO Gallagher to the VC firm

Two and a half years after Calistoga Pharmaceuticals was acquired by Gilead Sciences for up to $600m, Frazier Healthcare finally lured Calistoga's former CEO Carol Gallagher to help the venture capital firm replicate its successful investment in the cancer drug developer.

Cancer

Deals of the Week: IPO Window Raises Stakes For M&A

Rather than continue down the path to a public offering, Aragon sells to J&J for a hefty price. Also, MedImmune strikes a diabetes and obesity deal with NGM, Teva buys respiratory drug maker MicroDose, and Sanofi allies with the Curie Institute to study ovarian cancer.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Clifford J Stocks, CBO
    Roger Ulrich, PhD, Chief Development Officer
    Langdon L Miller, MD, EVP, R&D
  • Contact Info
  • Calistoga Pharmaceuticals Inc.
    Phone: (206) 728-4700
    2101 4th Ave.
    Ste. 1960
    Seattle, WA 98121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register